poisar

Filings · News reference

Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders

Benzinga Newsdesk

https://www.sec.gov/Archives/edgar/data/1401914/000149315226040265/forms-1.htm

More filings newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DARE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Benzinga Newsdesk

    Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure

    The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"

    DARE
  3. SEC EDGAR

    8-K filing — Dare Bioscience, Inc. (DARE)

    Filed: 2026-08-17 AccNo: 0001493152-26-038649 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    DARE